Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Praxis Precision Medicines, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Praxis Precision Medicines, Inc. (PRAX) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Praxis Precision Medicines, Inc. (“Praxis” or “the Company”) (NASDAQ: PRAX). Investors who purchased Praxis securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Praxis has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On August 4, 2025, Praxis announced its Q2 2025 financial results. The Company reported mid-stage clinical results from the trial of vormatrigine, an anti-seizure medication. Praxis admitted that more than half of patients experienced treatment-emergent adverse events, with almost 25% of study participants discontinuing the medication. Following this news, Praxis stock price dropped more than 5% on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Praxis securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
How Did Praxis Precision Medicines, Inc. (PRAX) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”